547 related articles for article (PubMed ID: 19195625)
1. The role of the lipogenic pathway in the development of hepatic steatosis.
Postic C; Girard J
Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
[TBL] [Abstract][Full Text] [Related]
3. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
5. Role of ChREBP in hepatic steatosis and insulin resistance.
Denechaud PD; Dentin R; Girard J; Postic C
FEBS Lett; 2008 Jan; 582(1):68-73. PubMed ID: 17716660
[TBL] [Abstract][Full Text] [Related]
6. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
7. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
8. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
10. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
Rafiq N; Younossi ZM
Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
[TBL] [Abstract][Full Text] [Related]
11. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
12. From the metabolic syndrome to NAFLD or vice versa?
Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
[TBL] [Abstract][Full Text] [Related]
13. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
Sanyal AJ
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():48-51. PubMed ID: 16225473
[TBL] [Abstract][Full Text] [Related]
14. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.
Wanless IR; Shiota K
Semin Liver Dis; 2004 Feb; 24(1):99-106. PubMed ID: 15085490
[TBL] [Abstract][Full Text] [Related]
15. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.
Bosserhoff A; Hellerbrand C
Dig Dis; 2011; 29(4):377-83. PubMed ID: 21894008
[TBL] [Abstract][Full Text] [Related]
16. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Choi SS; Diehl AM
Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
[TBL] [Abstract][Full Text] [Related]
17. Recent concepts in non-alcoholic fatty liver disease.
Adams LA; Angulo P
Diabet Med; 2005 Sep; 22(9):1129-33. PubMed ID: 16108837
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance and steatosis in humans.
Capeau J
Diabetes Metab; 2008 Dec; 34(6 Pt 2):649-57. PubMed ID: 19195626
[TBL] [Abstract][Full Text] [Related]
19. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model.
Kamada Y; Matsumoto H; Tamura S; Fukushima J; Kiso S; Fukui K; Igura T; Maeda N; Kihara S; Funahashi T; Matsuzawa Y; Shimomura I; Hayashi N
J Hepatol; 2007 Oct; 47(4):556-64. PubMed ID: 17459514
[TBL] [Abstract][Full Text] [Related]
20. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
